Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Internalized Components of Membrane Attack Complexes Disrupt Proteostasis and Acquire Alarmin-Like Properties.

bioRxiv : the preprint server for biology·2026
Same author

APOL1-risk alleles modulate T-cell receptor signaling to promote allograft rejection.

The Journal of clinical investigation·2026
Same author

Metabolic control of smooth muscle cell phenotype switching in atherosclerosis.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: A ZFYVE21-Rubicon-RNF34 signaling complex promotes endosome-associated inflammasome activity in endothelial cells.

Nature communications·2026
Same author

Increased medial collagen enhances aortic resilience against mural delamination from hydraulic fracturing.

bioRxiv : the preprint server for biology·2026
Same author

Hydraulic fracturing-induced delamination and extravasation extends medial damage beyond the false lumen in aortic dissection.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 16, 2026

Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

Interferon-gamma axis in graft arteriosclerosis.

George Tellides1, Jordan S Pober

  • 1Interdepartmental Program in Vascular Biology and Transplantation, Department of Surgery, Yale University School of Medicine, New Haven, CT, USA. george.tellides@yale.edu

Circulation Research
|March 17, 2007
PubMed
Summary

Interferon-gamma (IFN-gamma) drives graft arteriosclerosis, a major cause of cardiac allograft failure. Targeting the IFN-gamma axis may offer new therapeutic strategies for preventing chronic graft dysfunction.

More Related Videos

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

Related Experiment Videos

Last Updated: Jul 16, 2026

Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

Area of Science:

  • Immunology
  • Cardiology
  • Transplantation Biology

Background:

  • Cardiac allografts fail at 3-5% annually despite immunosuppression.
  • Graft arteriosclerosis, characterized by vascular stenosis, underlies chronic graft failure.
  • This process leads to secondary ischemic injury rather than direct immune damage.

Purpose of the Study:

  • To investigate the role of interferon-gamma (IFN-gamma) in graft arteriosclerosis.
  • To explore the IFN-gamma axis (including interleukin-12 and CXCR3 ligands) in T-cell activation and recruitment.
  • To review evidence supporting IFN-gamma's central role in chronic allograft dysfunction.

Main Methods:

  • Review of clinical observational studies.
  • Analysis of experimental animal studies.
  • Examination of IFN-gamma regulation, cellular effects, and therapeutic interventions.

Main Results:

  • IFN-gamma is proposed as a key effector in graft arteriosclerosis.
  • The IFN-gamma axis forms a positive feedback loop for T-cell responses.
  • Evidence from clinical and animal studies supports this hypothesis.

Conclusions:

  • Graft arteriosclerosis is a significant cause of long-term allograft failure.
  • The IFN-gamma axis plays a critical role in its pathogenesis.
  • Therapeutic strategies targeting IFN-gamma synthesis or signaling warrant development.